HHS lets compounding pharmacies offer six peptides the FDA has not approved
HHS will not penalize pharmacies that compound six unapproved peptides, overriding objections from FDA scientists.
Objective Facts
The Department of Health and Human Services posted an interim policy on Oct. 28, 2026, saying it will not act against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides the FDA has not approved: BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax. AJMC reported that Health Secretary Robert F. Kennedy Jr. signed the policy through his own office, and the Associated Press reported that most FDA scientific staff opposed it. CBS News said the policy requires patient-specific prescriptions, traceable ingredients, quality testing and adverse event reporting, and an HHS spokesperson told CBS it "does not grant FDA approval or establish clinical safety and effectiveness." The policy stays in place until the FDA finalizes a rule on its compounding bulks list, which the agency has not yet proposed, and public comment runs through Nov. 13.
Left-Leaning Perspective
Mainstream left-leaning coverage stressed that Kennedy went around his own scientists and that the evidence for these peptides is thin. ABC News's Youri Benadjaoud reported that no published clinical trials show the six peptides work in humans for any condition. CBS News, in a piece by Dr. Jon LaPook and Faris Tanyos, paired the policy with its own test of a bodega peptide sample that contained no peptide at all. Futurism's Maggie Harrison Dupré framed the move as opening the floodgates and quoted former FDA chief Janet Woodcock warning that it erodes the principle of testing drugs before wide use.
Right-Leaning Perspective
The right-of-center coverage we found came from libertarian outlets, which largely backed the move. Reason senior editor Elizabeth Nolan Brown called the policy a win for health freedom, argued that pharmacy-made peptides are safer than gray market imports and said the safeguards are reasonable, while noting the policy is a backdoor around an FDA that has not decided. Jeffrey A. Singer of the Reason Foundation, writing two days before the release, argued that adults should be free to accept uncertain risks and that blocking accountable suppliers pushes buyers to worse sources. We did not find opinion coverage of the final policy from The Wall Street Journal, National Review or Fox News.
Deep Dive
The policy grows out of a two-year fight. In 2023 the FDA placed BPC-157, TB-500 and other peptides on a list of substances that should not be compounded, citing risks such as immune reactions, according to the AP. Kennedy, who has called himself a "big fan" of peptides according to the AP, reshaped the FDA's compounding advisory panel, which in July voted to recommend six of seven peptides under review. AJMC reported that HHS then issued enforcement discretion through the Secretary's office after FDA staff resisted writing a rule declaring the products safe. Critics are on firm ground about the evidence: ABC News reported no published human trials show these peptides work for any condition, and FDA scientists flagged possible liver damage and allergic reactions, according to KFF Health News. Supporters have a point too. CBS News's own test found a bodega peptide product contained no peptide, which shows how unreliable the current market is, and the policy's conditions on sourcing, testing and adverse event reporting offer more oversight than online research chemical sales. Neither side has data on whether the new channel will replace the gray market or simply widen use, and supporters say less about the fact that enforcement discretion can be withdrawn at any time, leaving pharmacies without firm legal footing. Public comment closes Nov. 13, according to CBS News. AJMC reported that five more peptides go before the advisory committee in February, that HHS may revisit the policy if a safety signal appears, and that industry voices expect friction with state pharmacy regulators. Leerink's Michael Cherny told BioPharma Dive the notice falls short of the clearance telehealth firms such as Hims & Hers would need to scale up, so the FDA's eventual bulks list rule remains the decision that matters most.